Skip to main content
Fig. 1 | EJNMMI Research

Fig. 1

From: Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study

Fig. 1

Transaxial PET/CT images at the cervical level of a 55-year-old male melanoma patient undergoing immunotherapy with ipilimumab (ac). The PET/CT images before immunotherapy showed no pathologic lesions (a). Interim PET/CT performed after two cycles of ipilimumab demonstrated a new, small, 18F-FDG-avid subcutaneous lesion in the patient’s neck (white arrow; b), suspicious of metastatic involvement (uPMD, according to EORTC). A third PET/CT obtained soon after administration of four cycles of ipilimumab showed remission of the lesion (c), suggesting pseudoprogression of the cervical finding on interim PET/CT. The application of PERCIMT classified the patient as SMD already at the time of interim PET/CT, thus avoiding misinterpretation. At last follow-up the patient was still alive having reached an OS of 84.4 months

Back to article page